[go: up one dir, main page]

WO2006010498A3 - Diagnostics et therapeutiques pour des maladies associees a methionine aminopeptidase 2 (metap2) - Google Patents

Diagnostics et therapeutiques pour des maladies associees a methionine aminopeptidase 2 (metap2) Download PDF

Info

Publication number
WO2006010498A3
WO2006010498A3 PCT/EP2005/007707 EP2005007707W WO2006010498A3 WO 2006010498 A3 WO2006010498 A3 WO 2006010498A3 EP 2005007707 W EP2005007707 W EP 2005007707W WO 2006010498 A3 WO2006010498 A3 WO 2006010498A3
Authority
WO
WIPO (PCT)
Prior art keywords
diseases
metap2
therapeutics
diagnostics
diseases associated
Prior art date
Application number
PCT/EP2005/007707
Other languages
English (en)
Other versions
WO2006010498A2 (fr
Inventor
Stefan Golz
Ulf Brueggemeier
Andreas Geerts
Original Assignee
Bayer Healthcare Ag
Stefan Golz
Ulf Brueggemeier
Andreas Geerts
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Ag, Stefan Golz, Ulf Brueggemeier, Andreas Geerts filed Critical Bayer Healthcare Ag
Publication of WO2006010498A2 publication Critical patent/WO2006010498A2/fr
Publication of WO2006010498A3 publication Critical patent/WO2006010498A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/11—Aminopeptidases (3.4.11)
    • C12Y304/11018—Methionyl aminopeptidase (3.4.11.18)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

L'invention porte sur une METAP2 humaine associée à des maladies cardio-vasculaires, des infections, des maladies dermatologiques, des maladies endocrinologiques, des maladies métaboliques, des maladies gastroentérologiques, des cancers des inflammations, des maladies hématologiques, des maladies respiratoires, des maladies du squelette musculaires, des maladies neurologiques, des maladies urologiques. Cette invention concerne également des dosages pour l'identification de composés utiles dans le traitement ou la prévention de maladies cardio-vasculaires, d'infections, de maladies dermatologiques, de maladies endocrinologiques, des maladies métaboliques, des maladies gastroentérologiques, des cancers des inflammations, des maladies hématologiques, des maladies respiratoires, des maladies du squelette musculaires, des maladies neurologiques, des maladies urologiques. Cette invention se rapporte aussi à des composés qui se lient à METAP2 et/ou activent ou inhibent l'activité de METAP2, ainsi qu'à des compositions pharmaceutiques contenant ces composés.
PCT/EP2005/007707 2004-07-28 2005-07-15 Diagnostics et therapeutiques pour des maladies associees a methionine aminopeptidase 2 (metap2) WO2006010498A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04017833.7 2004-07-28
EP04017833 2004-07-28

Publications (2)

Publication Number Publication Date
WO2006010498A2 WO2006010498A2 (fr) 2006-02-02
WO2006010498A3 true WO2006010498A3 (fr) 2006-06-22

Family

ID=34981850

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2005/007707 WO2006010498A2 (fr) 2004-07-28 2005-07-15 Diagnostics et therapeutiques pour des maladies associees a methionine aminopeptidase 2 (metap2)

Country Status (1)

Country Link
WO (1) WO2006010498A2 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070254843A1 (en) * 2006-04-18 2007-11-01 Praecis Pharmaceuticals Incorporated Methods for treating bone associated diseases by the use of methionine aminopeptidase-2 inhibitors
WO2008066641A2 (fr) * 2006-11-06 2008-06-05 Praecis Pharmaceuticals Incorporated Procédé pour le traitement de maladies associées à mitf par l'utilisation d'inhibiteurs de méthionine aminopeptidase-2
WO2011085198A1 (fr) * 2010-01-08 2011-07-14 Zafgen Corporation Inhibiteur de metap-2 pour utilisation dans le traitement d'une hypertrophie bénigne de la prostate (bph)
US20130266578A1 (en) 2010-04-07 2013-10-10 Thomas E. Hughes Methods of treating an overweight subject
EP2763671A2 (fr) 2011-10-03 2014-08-13 Zafgen, Inc. Méthodes de traitement de troubles liés à l âge
WO2013169857A1 (fr) 2012-05-08 2013-11-14 Zafgen, Inc. Traitement de l'obésité hypothalamique au moyen d'inhibiteurs de metap2
JP6177888B2 (ja) 2012-05-09 2017-08-09 ザフゲン，インコーポレイテッド フマギロール型化合物ならびにその製造および使用方法
US9597309B2 (en) 2013-03-14 2017-03-21 Zafgen, Inc. Methods of treating renal disease and other disorders
AR105671A1 (es) 2015-08-11 2017-10-25 Zafgen Inc Compuestos heterocíclicos de fumagillol y sus métodos de elaboración y uso
CN106432255A (zh) 2015-08-11 2017-02-22 扎夫根公司 烟曲霉素醇螺环化合物和制备和使用其的方法

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998056372A1 (fr) * 1997-06-09 1998-12-17 Massachusetts Institute Of Technology Inhibiteurs de la methionine aminopeptidase de type 2 et leurs utilisations
US5888796A (en) * 1996-01-31 1999-03-30 St. Louis University Clone of a nucleotide sequence encoding a protein having two functions
US6136604A (en) * 1999-10-27 2000-10-24 Isis Pharmaceuticals Inc. Antisense inhibition of methionine aminopeptidase 2 expression
WO2001075177A2 (fr) * 2000-04-03 2001-10-11 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Marqueurs tumoraux pour le cancer des ovaires
US20020182701A1 (en) * 2001-08-30 2002-12-05 Saint Louis University Dominant negative variants of methionine aminopeptidase 2 (MetAP2) and clinical uses thereof
US6638750B1 (en) * 1999-03-11 2003-10-28 Pharmacia Corporation Methionine aminopeptidase type 3
US20030203406A1 (en) * 1999-03-11 2003-10-30 Sympson Carolyn J. Human methionine aminopeptidase type 3
US20030204070A1 (en) * 2002-01-23 2003-10-30 Jian Chen Polynucleotide encoding a novel methionine aminopeptidase, protease-39
WO2004092413A2 (fr) * 2003-04-18 2004-10-28 Novartis Ag Procedes de criblage genomique fonctionnels a debit eleve destines a l'osteoarthrite
WO2005016962A2 (fr) * 2003-08-11 2005-02-24 Genentech, Inc. Compositions et techniques de traitement de maladies liees a l'immunite

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5888796A (en) * 1996-01-31 1999-03-30 St. Louis University Clone of a nucleotide sequence encoding a protein having two functions
WO1998056372A1 (fr) * 1997-06-09 1998-12-17 Massachusetts Institute Of Technology Inhibiteurs de la methionine aminopeptidase de type 2 et leurs utilisations
US20010034455A1 (en) * 1997-06-09 2001-10-25 Liu Jun O. Type 2 methionine aminopeptidase (MetAP2) inhibitors and uses thereof
US6638750B1 (en) * 1999-03-11 2003-10-28 Pharmacia Corporation Methionine aminopeptidase type 3
US20030203406A1 (en) * 1999-03-11 2003-10-30 Sympson Carolyn J. Human methionine aminopeptidase type 3
US6136604A (en) * 1999-10-27 2000-10-24 Isis Pharmaceuticals Inc. Antisense inhibition of methionine aminopeptidase 2 expression
WO2001075177A2 (fr) * 2000-04-03 2001-10-11 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Marqueurs tumoraux pour le cancer des ovaires
US20020182701A1 (en) * 2001-08-30 2002-12-05 Saint Louis University Dominant negative variants of methionine aminopeptidase 2 (MetAP2) and clinical uses thereof
US20030204070A1 (en) * 2002-01-23 2003-10-30 Jian Chen Polynucleotide encoding a novel methionine aminopeptidase, protease-39
WO2004092413A2 (fr) * 2003-04-18 2004-10-28 Novartis Ag Procedes de criblage genomique fonctionnels a debit eleve destines a l'osteoarthrite
WO2005016962A2 (fr) * 2003-08-11 2005-02-24 Genentech, Inc. Compositions et techniques de traitement de maladies liees a l'immunite

Also Published As

Publication number Publication date
WO2006010498A2 (fr) 2006-02-02

Similar Documents

Publication Publication Date Title
WO2005093092A3 (fr) Diagnostic et traitement de maladies associees au recepteur 44 couple aux proteines g (gpr44)
WO2006027147A3 (fr) Agents diagnostiques et therapeutiques destines a des maladies associees au recepteur d'adrenomedulline (amdr)
WO2006010498A3 (fr) Diagnostics et therapeutiques pour des maladies associees a methionine aminopeptidase 2 (metap2)
WO2005106012A3 (fr) Diagnostics et therapeutiques de maladies associees a la dipeptidyl-peptidase 1 (dpp1)
WO2005100990A3 (fr) Methodes diagnostiques et therapeutiques pour des maladies associees au purinocepteur 2 de type y (p2y2)
WO2006010514A3 (fr) Diagnostic et traitement therapeutique des maladies associees a la proteine kinase kinase 5 activee par les mitogenes (map2k5) a double specificite
WO2006010494A3 (fr) Moyens de diagnostic et de traitement pour des maladies associees a la methionine aminopeptidase 1 (metap1)
WO2005113786A3 (fr) Methodes diagnostiques et therapeutiques pour lutter contre des maladies associees a la chymase (cma1)
WO2005106486A3 (fr) Diagnostics et therapeutiques de maladies associees a la dipeptidyl-peptidase 3 (dpp3)
WO2005075675A3 (fr) Outils de diagnostic et de traitement de maladies associees a la cysteine protease putative 1 (prsc1)
WO2005093091A3 (fr) Agents diagnostiques et therapeutiques pour maladies associees au recepteur 26 couple a la proteine g (gpr26)
WO2005076007A3 (fr) Diagnostics et traitements de maladies associees au recepteur p2y12 couple a la proteine g (p2y12)
WO2006021343A3 (fr) Diagnostic et therapie de maladies associees au recepteur 3a de la 5-hydroxytryptamine (5-ht3a)
WO2005100997A3 (fr) Moyens diagnostiques et therapeutiques pour maladies associees au recepteur de tachykinine 3 (tacr3)
WO2006013012A3 (fr) Diagnostics et therapeutique pour maladies liees a la napsine 1 (nap1)
WO2006013015A3 (fr) Diagnostics et therapeutique pour maladies liees a la marapsine (mpn)
WO2006005470A3 (fr) Agents diagnostiques et therapeutiques pour des maladies associees au recepteur couple a la proteine g lie au mas (mrge)
WO2005101009A3 (fr) Outils diagnostiques et therapeutiques pour maladies associees au recepteur 2 de tachykinine (tacr2)
WO2005026719A3 (fr) Diagnostic et traitement de maladies associees au transporteur de cations organiques slc22a3 (slc22a3)
WO2005114210A8 (fr) Methodes diagnostiques et therapeutiques pour lutter contre les maladies associees a la kinase 3 specifique du recepteur couple a une proteine g (grk3)
WO2006010497A3 (fr) Diagnostics et therapeutiques pour des maladies associees a choline kinase (chk)
WO2006010495A3 (fr) Moyens de diagnostic et de traitement pour des maladies associees a la carboxypeptidase a3 (cpa3)
WO2005052586A3 (fr) Elements de diagnostic et de therapie pour des maladies associees au canal potassique, sous famille k et element 3 (kcnk3)
WO2005119263A3 (fr) Diagnostic et traitement des maladies associees au recepteur couple aux proteines g 92 (gpr92)
WO2005113788A3 (fr) Diagnostics et therapeutiques pour des maladies associees a la kinase 6 associee au recepteur couple a une proteine g (grk6)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase